MedPath

Biopsychosocial Predictors of Nicotine Relapse

Not Applicable
Recruiting
Conditions
Smoking
Smoking Cessation
Nicotine Addiction
Tobacco Smoking Behavior
Registration Number
NCT06470321
Lead Sponsor
University of Cyprus
Brief Summary

This study aims to investigate the associations between emotion regulation ability, stress-induced neural activity changes, and susceptibility to relapse in smokers attempting to quit. Participants will undergo assessments of emotion regulation, neural activity via quantitative electroencephalography (qEEG), and stress responses before and during a 24-hour nicotine abstinence period. They will then participate in a computerized smoking cessation intervention, and their abstinence status will be monitored for 6 months.

Detailed Description

The study will examine the unique and interactive effects of emotion regulation ability (a trait-like vulnerability factor) and biomarkers of stress responses (emotion regulation and neural activation changes) prior to smoking cessation, on cravings, abstinence adherence, and response to a smoking cessation intervention.

The study will be divided into three main phases:

* Ad libitum nicotine use (Day 1): Participants will smoke as usual. Baseline assessments of emotion regulation (heart rate variability), neural activity (qEEG), stress responses (salivary cortisol), and nicotine craving will be conducted before and after exposure to a stress task.

* Acute 24-hour abstinence (Day 2): Participants will abstain from smoking for 24 hours. Emotion regulation, neural activity, withdrawal symptoms, and cue-induced cravings will be assessed.

* Smoking cessation intervention (Days 3 to 180): Participants will engage in a computerized smoking cessation program. Abstinence will be biochemically verified at 3 and 6 months post-quit. Smoking lapses and time to relapse will also be monitored.

The primary outcomes are maintenance of abstinence, smoking lapses, and time to relapse. Secondary outcomes include changes in emotion regulation, neural activity, stress responses, withdrawal symptoms, and cue-induced cravings.

The study hypothesizes that smokers who fail to maintain long-term abstinence will exhibit enhanced stress-induced high-frequency qEEG oscillations, disrupted connectivity in emotion regulation brain regions, and emotion regulation deficits. It is also hypothesized that the interplay between these measures will predict smoking cessation outcomes.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Age 18-60 years
  • Smoking at least 10 cigarettes daily for at least 2 years
  • Intention to quit smoking
  • Medication-free
Exclusion Criteria
  • Presence of psychiatric or medical treatment
  • Pregnancy
  • Current unstable medical illness
  • Recent (prior 6 months) drug or alcohol use disorder
  • Major Depression
  • Diagnosis of psychotic disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Time to First Smoking Lapse6 months

Defined as the number of days between the quit date and the first smoking lapse (smoking even a puff of a cigarette). Smoking lapses will be monitored continuously via self-report.

Maintenance of AbstinenceMeasured at 3 and 6 month follow-ups

Defined as biochemically verified (via expired carbon monoxide) continuous abstinence from smoking for the full 6 month period after the quit date

Secondary Outcome Measures
NameTimeMethod
Withdrawal SymptomsBaseline, 24 hours

Assessed via standardized withdrawal symptom questionnaires at baseline and after 24 hours of abstinence.

Stress ResponsesBaseline, 24 hours

Salivary cortisol levels measured before and after stress exposure at baseline and 24-hour timepoints

Emotion RegulationBaseline, 24 hours

Measured via heart rate variability before and after stress exposure at baseline and 24-hour timepoints

Neural ActivityBaseline, 24 hours

Quantitative EEG spectral power and coherence between brain regions involved in emotion regulation assessed at baseline and after 24-hour abstinence.

© Copyright 2025. All Rights Reserved by MedPath